Scholarlink

Background and Methods <p>We conducted a single-center cross-sectional study to investigate racial disparities in the hesitancy and utilization of monoclonal antibody (mAb) treatment of COVID-19 among treatment eligible patients who were referred to the infusion center between January 4, 2021, and May 14, 2021.</p> Results <p>Among the 2406 eligible participants, mAb treatment was significantly underutilized among African American patients compared to White patients (OR 1.8; 95% CI 1.5–2.1). The higher proportion of refusals and cancellations of mAb treatment may suggest a higher level of hesitancy among African American patients (OR 1.7; 95% CI 1.3–2.1).</p> Conclusion <p>Evaluating the reasons and addressing racial disparities in hesitancy of novel therapeutics under Emergency Use Authorization (EUA) offer a critical opportunity to address the inequities in pandemic care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Racial Disparities in Hesitancy and Utilization of Monoclonal Antibody Infusion Treatment of COVID-19: Lessons for Future Pandemics

  • 期刊论文

  • 发表日期：

    2025年2月26日

查看全文
  • Yahya Shaikh,
  • Ishaan Gupta,
  • Sophia Purekal,
  • Mary Jane E. Vaeth,
  • Maisha Foyez,
  • Charles D. Callahan,
  • Maryam Elhabashy,
  • Minahil Cheema,
  • Resham Rahat,
  • James R. Ficke,
  • Albert W. Wu,
  • Paul G. Auwaerter,
  • Melinda E. Kantsiper,
  • Zishan K. Siddiqui

摘要

Background and Methods

We conducted a single-center cross-sectional study to investigate racial disparities in the hesitancy and utilization of monoclonal antibody (mAb) treatment of COVID-19 among treatment eligible patients who were referred to the infusion center between January 4, 2021, and May 14, 2021.

Results

Among the 2406 eligible participants, mAb treatment was significantly underutilized among African American patients compared to White patients (OR 1.8; 95% CI 1.5–2.1). The higher proportion of refusals and cancellations of mAb treatment may suggest a higher level of hesitancy among African American patients (OR 1.7; 95% CI 1.3–2.1).

Conclusion

Evaluating the reasons and addressing racial disparities in hesitancy of novel therapeutics under Emergency Use Authorization (EUA) offer a critical opportunity to address the inequities in pandemic care.